TNF and cancer: Indeed, when a small panel of mouse cancer cells was evaluated for sensitivity to LCL161 + TNFα and three additional lines chosen for in vivo testing based on degree of sensitivity (Supplementary Figs. 5 and 22) and known immunogenicity13–15 (Supplementary Fig. 6), the shared characteristic among the responsive (EMT6 breast carcinoma and M3-9-M rhabdomyosarcoma) vs. resistant (76–9 rhabdomyosarcoma and 4T1 breast carcinoma) tumors in vivo was immunogenicity, not sensitivity to LCL161 + TNFα in vitro (Fig. 1g–i).